⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15863920 | 0.77 | — | — | |
| SCHEMBL2273487 | 0.69 | — | — | |
| SCHEMBL31217636 | 0.67 | — | — | |
| SCHEMBL28773909 | 0.67 | — | — | |
| SCHEMBL14982846 | 0.65 | — | — | |
| SCHEMBL8970834 | 0.65 | — | — | |
| SCHEMBL31463483 | 0.65 | — | — | |
| SCHEMBL7120179 | 0.63 | — | — | |
| SCHEMBL20873161 | 0.61 | ALDH1A1 (0.46) | — | |
| SCHEMBL595 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12351577-B2 | Inhibiting cyclic AMP-responsive element-binding protein (CREB) | FORMA THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250129112-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | MITOPOWER, INC. | 2025-04-24 | — | — | US | disclosed |
| CN-119677738-A | Compounds and uses thereof | 福宏治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4522280-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12168673-B2 | Prodrugs derived from nicotinic acid and ribose | MITOPOWER, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4463158-A2 | NOVEL PRODRUGS DERIVED FROM NICOTINIC ACID AND RIBOSE | Mitopower, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12139487-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118922189-A | Novel prodrugs derived from niacin and ribose | 线粒体能量有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-115710202-A | Preparation method and application of apatazone key intermediate | 江西同和药业股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| WO-2023021026-A1 | A SYNTHETIC PATHWAY TO ESTRA-1,3,5(10)-TRIENE-3,15A,16A,17B-TETROL | ASPEN OSS B.V. (NL) | 2023-02-23 | — | — | WO | disclosed |
| US-20230015215-A1 | EVALUATION METHOD OF DIFFERENTIATION STATE OF CELLS, AND CELL CULTURE SYSTEM | HITACHI HIGH-TECH CORPORATION (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4092129-A1 | EVALUATION METHOD OF DIFFERENTIATION STATE OF CELLS, AND CELL CULTURE SYSTEM | Hitachi High-Tech Corporation (JP) | 2022-11-23 | — | — | EP | disclosed |
| CN-115297861-A | Compound and use thereof | 福宏治疗公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220213089-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | FORMA THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022103899-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |